(Q37768172)

22 August 2017

1 reference

title

Classical neurotransmitters and neuropeptides involved in major depression: a review (English)

1 reference

22 August 2017

1 reference

2

Rafael Coveñas

1 reference

22 August 2017

Felix-Martin Werner

1

1 reference

22 August 2017

publication date

1 July 2010

1 reference

International Journal of Neuroscience

22 August 2017

published in

1 reference

22 August 2017

volume

120

1 reference

22 August 2017

issue

7

1 reference

22 August 2017

page(s)

455-470

1 reference

Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders.

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Dysregulation of GABAergic neurotransmission in mood disorders: a postmortem study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Selective blockade of 5-hydroxytryptamine (5-HT)7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Extended-release bupropion: an antidepressant with a broad spectrum of therapeutic activity?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Substance P in serum and cerebrospinal fluid of depressed patients: no effect of antidepressant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Anxious-retarded depression: relation to two-year outcome of major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

GABAergic control of adult hippocampal neurogenesis in relation to behavior indicative of trait anxiety and depression states

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Neuroactive steroids and affective disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Bupropion: pharmacology and therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Combined actions of zinc and fluoxetine on nicotinic acetylcholine receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Thyroid indices and response to fluoxetine and nortriptyline in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Elevated cerebrospinal fluid substance p concentrations in posttraumatic stress disorder and major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Cortisol responses to combined dexamethasone/CRH test in outpatients with a major depressive episode.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Depressive symptoms, major depressive episode and cognition in the elderly: the three-city study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Depression with above-normal plasma vasopressin: validation by relations with family history of depression and mixed anxiety and retardation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Cholecystokinin and endogenous opioid peptides: interactive influence on pain, cognition, and emotion

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Neuropeptide Y (NPY) shortens sleep latency but does not suppress ACTH and cortisol in depressed patients and normal controls

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Effect of flumazenil-augmentation on microsleep and mood in depressed patients during partial sleep deprivation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Association between glutamic acid decarboxylase genes and anxiety disorders, major depression, and neuroticism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

CSF serotonin, 5-hydroxyindolacetic acid and neuropeptide Y levels in severe major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Simultaneous use of thyrotropin-releasing hormone test and combined dexamethasone/corticotropine-releasing hormone test for severity evaluation and outcome prediction in patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Association study of nicotinic-receptor variants and major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Selective 5-HT receptor inhibition of glutamatergic and GABAergic synaptic activity in the rat dorsal and median raphe

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

The HPA and immune axes in stress: the involvement of the serotonergic system

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

No modulatory effect of neurokinin-1 receptor antagonists on serotonin uptake in human and rat brain synaptosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Serum levels of substance P and response to antidepressant pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Reduced anxiety and depression-like behaviors in mice lacking GABA transporter subtype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Corticotropin-releasing hormone, arginine vasopressin, gastrin-releasing peptide, and neuromedin B alterations in stress-relevant brain regions of suicides and control subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Elevated putamen D(2) receptor binding potential in major depression with motor retardation: an [11C]raclopride positron emission tomography study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Increased arginine vasopressin mRNA expression in the human hypothalamus in depression: A preliminary report.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Dopamine transporter density may be associated with the depressed affect in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Antidepressant-like activity of CGP 36742 and CGP 51176, selective GABAB receptor antagonists, in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

The other face of depression, reduced positive affect: the role of catecholamines in causation and cure

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Are compounds acting at metabotropic glutamate receptors the answer to treating depression?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Depression and poor sleep: the effect of monoaminergic antidepressants in a pre-clinical model in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

The influence of 4-week treatment with sertraline on the combined T3/TRH test in depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Time course of hypothalamic-pituitary-adrenocortical axis activity during treatment with reboxetine and mirtazapine in depressed patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Neuropeptide expression in rats exposed to chronic mild stresses.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Central alpha1-adrenergic system in behavioral activity and depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Comparison of the effectiveness of reboxetine versus fluoxetine in patients with atypical depression: a single-blind, randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Depression of glutamate and GABA release by presynaptic GABAB receptors in the entorhinal cortex in normal and chronically epileptic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Enhanced anxiety, depressive-like behaviour and impaired recognition memory in mice with reduced expression of the vesicular glutamate transporter 1 (VGLUT1)

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Evidence of common and specific genetic effects: association of the muscarinic acetylcholine receptor M2 (CHRM2) gene with alcohol dependence and major depressive syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Chronic ACTH autoantibodies are a significant pathological factor in the disruption of the hypothalamic-pituitary-adrenal axis in chronic fatigue syndrome, anorexia nervosa and major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Norepinephrine transporter inhibitors and their therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

The risk for depression conferred by stressful life events is modified by variation at the serotonin transporter 5HTTLPR genotype: evidence from the Spanish PREDICT-Gene cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

Neue Wege in der Depressionsbehandlung

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2010.483651

10.3109/00207454.2010.483651

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference